Litigation Note: Crowell & Moring Secures IP Victory for Apotex
Firm News | less than 1 min read | 10.01.15
Washington, D.C. - October 1, 2015: Crowell & Moring represented Apotex in successfully challenging the validity of U.S. Patent No. 8,324,283 before the U.S. Patent and Trademark Office Patent Trial and Appeals Board (PTAB). Apotex, along with generic pharmaceutical companies Torrent Pharmaceuticals and Mylan Pharmaceuticals, petitioned the PTAB to invalidate the '283 patent related to oral formulations for the administration of the multiple sclerosis drug fingolimod, marketed by Novartis as Gilenya®. As a result, all claims of the '283 patent were found invalid by PTAB.
Insights
Firm News | 2 min read | 09.20.24
Crowell & Moring Secures Zero-Payment Dismissal for BMW Group Against Infogation
Crowell & Moring LLP is pleased to announce that firm client BMW Group has achieved a zero-payment dismissal with prejudice in two cases brought by Infogation Corporation (“Infogation”) against Bayerische Motoren Werke AG (“BMW AG”) and BMW of North America, LLC (“BMW NA”) involving U.S. Patent Nos. 10,107,628; 8,898,003; 8,406,994; and 6,292,743 (“Patents-in-Suit”), before the U.S. District Court for the Eastern District of Texas.
Firm News | 2 min read | 09.17.24
Firm News | 2 min read | 09.10.24
John Koenigsknecht and Andrew Avsec Named as Crain’s Chicago Business 2024 Notable Leaders in Law
Firm News | 2 min read | 09.09.24
Daily Journal Names Jason Murray and Chahira Solh to 2024 Top 100 Lawyers List